Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 83
Filter
1.
Am J Case Rep ; 22: e927556, 2021 Jan 12.
Article in English | MEDLINE | ID: mdl-33431787

ABSTRACT

BACKGROUND Fibrosing mediastinitis is a rarely seen, progressive disease. It results from an excessive fibrotic reaction in the mediastinum. We describe a presentation of fibrosing mediastinitis that, to our knowledge, has never been seen before. CASE REPORT A 30-year-old female Colombian flight attendant presented with a right eyelid droop. Examination revealed partial right-sided ptosis and miosis but no anhidrosis. An ill-defined firm swelling was palpable at the root of the neck. Chest radiography revealed a widened mediastinum, and computerized tomography (CT) showed a right paratracheal mass without calcification extending to the thoracic inlet, encasing multiple blood vessels. All basic blood tests, magnetic resonance imaging of the head, and ultrasound Doppler of the neck vessels were normal. History and work up for infections including fungal diseases, granulomatous diseases, vasculitis, and autoimmune diseases were negative. Positron emission tomography (PET) showed significant FDG uptake in the mediastinum. Mediastinal biopsy was histologically consistent with fibrosing mediastinitis. All relevant immunohistochemistry and microbiological studies were negative. Subsequently, the patient developed signs of superior vena cava compression; this was managed by balloon angioplasty, which resulted in improvement of symptoms. However, over time, her symptoms worsened progressively, resulting in a left-sided ptosis and radiological progression of the mass on CT. She received treatment with rituximab and concomitant steroids, which yielded excellent results: the treatment led to both resolution of her symptoms and regression of the mass and its metabolic activity on PET scan. CONCLUSIONS Fibrosing mediastinitis can present with an incomplete Horner's syndrome. Treatment with rituximab and steroids shows promising results in select cases of metabolically active idiopathic fibrosing mediastinitis.


Subject(s)
Blepharoptosis/etiology , Mediastinitis/complications , Mediastinitis/diagnosis , Miosis/etiology , Sclerosis/complications , Sclerosis/diagnosis , Adult , Female , Humans , Mediastinitis/therapy , Sclerosis/therapy
2.
J Gynecol Obstet Hum Reprod ; 50(6): 101734, 2021 Jun.
Article in English | MEDLINE | ID: mdl-32283225

ABSTRACT

We describe the first French patient treated for sclerosing peritonitis syndrome associated with lutheinized thecomas. At 42 years old, she had respiratory distress with increased abdominal volume. Physical examination revealed ascites, pleural effusions, and two mobile latero-uterine masses. Radiological examinations revealed bilateral ovarian masses of 10 cm. Bilateral adnexectomy was performed by laparotomy. Histological analysis concluded that there were benign luteinized thecomas. Until the 36th postoperative day, the general condition of the patient deteriorated to become critical. A second surgical procedure was attempted revealing sclerosing fibrosis preventing access to the peritoneal cavity. Subsequently, a medical treatment combining parenteral nutrition, high intravenous doses of corticosteroids, antiestrogens, colchicine and sandostatin was administered and effective allowing continuity recovery 15 months later. The clinical outcomes has been favorable at 24 month later.


Subject(s)
Ovarian Neoplasms/surgery , Peritonitis/therapy , Remission Induction , Sclerosis/therapy , Thecoma/surgery , Adult , Antineoplastic Agents, Hormonal/therapeutic use , Colchicine/therapeutic use , Estrogen Receptor Modulators/therapeutic use , Female , Glucocorticoids/therapeutic use , Humans , Octreotide/therapeutic use , Ovarian Neoplasms/complications , Parenteral Nutrition , Peritoneum/pathology , Peritonitis/complications , Sclerosis/complications , Thecoma/complications
4.
Catheter Cardiovasc Interv ; 94(6): 878-885, 2019 Nov 15.
Article in English | MEDLINE | ID: mdl-30790443

ABSTRACT

Fibrosing mediastinitis is a rare, often debilitating and potentially lethal disease characterized by an exuberant fibroinflammatory response within the mediastinum. Patients typically present with insidious symptoms related to compression of adjacent structures including the esophagus, heart, airways, and cardiac vessels. Fibrosing mediastinitis is most often triggered by Histoplasmosis infection; however, antifungal and anti-inflammatory therapies are largely ineffective. While structural interventions aimed at alleviating obstruction can provide significant palliation, surgical interventions are challenging with high mortality and clinical experience with percutaneous interventions is limited. Here, we will review the presentation, natural history, and treatment of fibrosing mediastinitis, placing particular emphasis on catheter-based therapies.


Subject(s)
Airway Obstruction/therapy , Bronchoscopy , Endovascular Procedures , Histoplasmosis/therapy , Mediastinitis/therapy , Pulmonary Veno-Occlusive Disease/therapy , Sclerosis/therapy , Stenosis, Pulmonary Artery/therapy , Adolescent , Adult , Aged , Airway Obstruction/diagnostic imaging , Airway Obstruction/microbiology , Airway Obstruction/mortality , Bronchoscopy/adverse effects , Bronchoscopy/instrumentation , Bronchoscopy/mortality , Child , Endovascular Procedures/adverse effects , Endovascular Procedures/instrumentation , Endovascular Procedures/mortality , Female , Histoplasmosis/diagnostic imaging , Histoplasmosis/microbiology , Histoplasmosis/mortality , Humans , Male , Mediastinitis/diagnostic imaging , Mediastinitis/microbiology , Mediastinitis/mortality , Middle Aged , Pulmonary Veno-Occlusive Disease/diagnostic imaging , Pulmonary Veno-Occlusive Disease/mortality , Risk Factors , Sclerosis/diagnostic imaging , Sclerosis/microbiology , Sclerosis/mortality , Stenosis, Pulmonary Artery/diagnostic imaging , Stenosis, Pulmonary Artery/mortality , Stents , Treatment Outcome , Young Adult
5.
Mult Scler Relat Disord ; 28: 129-131, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30594812

ABSTRACT

OBJECTIVE: To report a patient presented with diplopia followed by progressive quadriparesis in the setting of a solitary pontomedullary lesion. CASE PRESENTATION: We report a 24-year-old woman presented with an attack of diplopia with full recovery, followed by progressive quadriparesis. The patient had a single pontomedullary lesion. Extensive diagnostic work up was negative. After follow up for 6 years, despite of clinical deterioration, the patient had the same pontomedullary lesion consistent with progressive solitary sclerosis. Corticosteroid pulse therapy and rituximab, didn't yield significant improvement, and the course was progressive, but after adding cyclophosphamide, partial improvement was seen. CONCLUSION: Progressive solitary sclerosis can cause progressive quadriparesis after an attack of diplopia without evidence of dissemination in time and space even after a prolonged period. This rare entity should be included in differential diagnosis of demyelinating lesions.


Subject(s)
Demyelinating Autoimmune Diseases, CNS/complications , Demyelinating Autoimmune Diseases, CNS/diagnosis , Diplopia/complications , Diplopia/diagnosis , Brain Stem/diagnostic imaging , Demyelinating Autoimmune Diseases, CNS/therapy , Diagnosis, Differential , Diplopia/therapy , Disease Progression , Female , Humans , Quadriplegia/diagnosis , Quadriplegia/etiology , Quadriplegia/therapy , Sclerosis/complications , Sclerosis/diagnosis , Sclerosis/therapy , Young Adult
6.
Rev Chil Pediatr ; 89(3): 399-408, 2018 Jun.
Article in Spanish | MEDLINE | ID: mdl-29999148

ABSTRACT

Myopathies secondary to collagen VI mutations (COLVI-M) are the most frequent in the northern hemisphere, affecting the adult and pediatric population. There are no data on its prevalence in Latin America. They are characterized by a great clinical variability, from severe phenotypes, such as Ullrich congenital muscular dystrophy (UCMD), to intermediate and mild ones such as Bethlem myopathy (BM). Its onset is also variable and extends from the neonatal period to adulthood. Given the presence of joint hypermobility, the differential diagnosis should be made with various connective tissue diseases. The classical diagnostic algorithm in many patients has been insufficient to guide the genetic study in an adequate way, and from this the muscular magnetic resonance imaging has emerged as a very useful tool for a better diagnostic approach of this and other muscular pathologies. This ob jective of this review is to study the forms of presentation, clinical characteristics, specific diagnostic study, differential diagnosis and management of one of the most frequent hereditary muscular patho logies, with emphasis on the contribution of muscle magnetic resonance imaging.


Subject(s)
Collagen Type VI/genetics , Contracture/diagnosis , Muscular Dystrophies/congenital , Sclerosis/diagnosis , Contracture/genetics , Contracture/therapy , Diagnosis, Differential , Genetic Markers , Genetic Testing , Humans , Magnetic Resonance Imaging , Muscular Dystrophies/diagnosis , Muscular Dystrophies/genetics , Muscular Dystrophies/therapy , Mutation , Physical Examination , Sclerosis/genetics , Sclerosis/therapy
7.
Rev. chil. pediatr ; 89(3): 399-408, jun. 2018. tab, graf
Article in Spanish | LILACS | ID: biblio-959540

ABSTRACT

Resumen: Las miopatías secundarias a mutaciones en el colágeno VI (M-COLVI) son las más frecuentes en el hemisferio norte, afectando población adulta y pediátrica. No existen datos de su prevalencia en Latinoamérica. Se caracterizan por presentar una gran variabilidad clínica, desde fenotipos severos, como la distrofia muscular congénita de Ullrich (DMCU), a intermedios y leves como la Miopatía de Bethlem (MB). Su inicio también es variable y se extiende desde el período de recién nacido hasta la vida adulta. Dada la presencia de hiperlaxitud articular, el diagnóstico diferencial se debe realizar con diversas enfermedades del tejido conectivo. El algoritmo diagnóstico clásico en muchos pacientes ha sido insuficiente para orientar el estudio genético de forma adecuada, y a partir de esto la resonancia magnética muscular ha emergido como una herramienta de gran utilidad para una mejor aproxima ción diagnóstica de ésta y otras patologías musculares. Esta revisión tiene como objetivo examinar las formas de presentación, características clínicas, estudio diagnóstico específico, diagnóstico dife rencial y manejo de una de las patologías musculares herediatarias más frecuentes, con énfasis en el aporte de la resonancia magnética muscular.


Abstract: Myopathies secondary to collagen VI mutations (COLVI-M) are the most frequent in the northern hemisphere, affecting the adult and pediatric population. There are no data on its prevalence in Latin America. They are characterized by a great clinical variability, from severe phenotypes, such as Ullrich congenital muscular dystrophy (UCMD), to intermediate and mild ones such as Bethlem myopathy (BM). Its onset is also variable and extends from the neonatal period to adulthood. Given the presence of joint hypermobility, the differential diagnosis should be made with various connective tissue diseases. The classical diagnostic algorithm in many patients has been insufficient to guide the genetic study in an adequate way, and from this the muscular magnetic resonance imaging has emerged as a very useful tool for a better diagnostic approach of this and other muscular pathologies. This ob jective of this review is to study the forms of presentation, clinical characteristics, specific diagnostic study, differential diagnosis and management of one of the most frequent hereditary muscular patho logies, with emphasis on the contribution of muscle magnetic resonance imaging.


Subject(s)
Humans , Sclerosis/diagnosis , Contracture/diagnosis , Collagen Type VI/genetics , Muscular Dystrophies/congenital , Physical Examination , Sclerosis/genetics , Sclerosis/therapy , Magnetic Resonance Imaging , Genetic Markers , Genetic Testing , Contracture/genetics , Contracture/therapy , Diagnosis, Differential , Muscular Dystrophies/diagnosis , Muscular Dystrophies/genetics , Muscular Dystrophies/therapy , Mutation
9.
J Hand Surg Am ; 43(5): 465-469, 2018 05.
Article in English | MEDLINE | ID: mdl-29573896

ABSTRACT

Kienböck disease is uncommon in skeletally immature patients. Although there is no gold standard treatment for Kienböck disease in the skeletally immature patient, surgical and nonsurgical treatment options have been shown to be effective. Initial immobilization with a cast, protection with an orthosis, and avoidance of repetitive forceful activities have been shown to be effective in some cases. Surgery may be offered to the skeletally immature patient when nonsurgical treatment is ineffective. Among several surgical techniques used for treatment in the skeletally immature patient with Kienböck disease, distal radial osteotomies have been the most frequently performed surgery; however, radial overgrowth is a concern. There is a great potential for revascularization and remodeling of the lunate in the skeletally immature patients with Kienböck disease. Good and excellent clinical and radiological outcomes can be achieved with both nonsurgical and surgical treatments.


Subject(s)
Osteonecrosis/therapy , Adolescent , Athletes , Casts, Surgical , Female , Hand Strength/physiology , Humans , Lunate Bone/diagnostic imaging , Magnetic Resonance Imaging , Male , Osteonecrosis/diagnostic imaging , Osteonecrosis/physiopathology , Osteotomy , Radius/surgery , Range of Motion, Articular/physiology , Risk Factors , Sclerosis/diagnostic imaging , Sclerosis/physiopathology , Sclerosis/therapy , Splints , Tomography, X-Ray Computed , Wrist Joint/physiopathology
10.
Radiología (Madr., Ed. impr.) ; 59(5): 401-413, sept.-oct. 2017. tab, graf, ilus
Article in Spanish | IBECS | ID: ibc-165916

ABSTRACT

Objetivo. Estudio estadístico del éxito, el número de sesiones necesarias y la duración global del tratamiento percutáneo con esclerosantes de malformaciones linfáticas pediátricas que oriente la elección del esclerosante. Material y métodos. Estudio retrospectivo basado en los resultados obtenidos durante 14 años por Radiología Intervencionista Pediátrica en el tratamiento percutáneo de malformaciones linfáticas macroquísticas realizado en 56 pacientes. El procedimiento consiste en introducir el esclerosante bajo control ecográfico como único tratamiento, repitiendo las sesiones en ausencia de respuesta o sintomatología persistente hasta el alta. Se realiza un análisis descriptivo y estadístico del éxito, el número de sesiones y la duración del tratamiento para la obtención de conclusiones. Resultados. Se excluyen los pacientes perdidos en el seguimiento y los tratados con agentes concretos, con un número final de 52 pacientes tratados con OK432 (n=29), Ethibloc (n=5) y terapia combinada (n=18). El promedio de las sesiones y la duración (meses) del tratamiento fueron, respectivamente, de 2,38 sesiones y 8,6 meses para OK432, 1,4 sesiones y 5,6 meses para Ethibloc, y 1,83 sesiones y 2,30 meses para la terapia dual. Los resultados fueron estadísticamente significativos en la diferencia de la duración del tratamiento entre OK432 y la terapia dual. No hubo diferencias en el éxito ni en el número de sesiones, al igual que entre otras variables demográficas y anatómicas, en favor de la homogeneidad de la muestra. Conclusiones. Las diferencias entre un tratamiento más prolongado con OK432 frente a la terapia dual podrían suponer un mayor gasto sanitario y más frecuentación hospitalaria, con un mayor inconveniente para familiares y pacientes (AU)


Objective. Analyze statistically the success, number of sessions required and complete duration of treatment of agents used in pediatric percutaneous sclerotherapy of lymphatic malformations, to determine the most suitable. Material and methods. Retrospective study based on outcomes from percutaneous sclerotherapy performed on lymphatic malformations of 56 patients conducted by pediatric interventional radiologist for 14 years. As first approach, the procedure consists of ultrasound-guided introduction of sclerosing agent. Sessions were repeated until clinical resolution. Success, number of sessions and the duration of treatment were recorded and statistical treatment of the data was performed to obtain further conclusions. Results. Lost patients in follow up and other minority agents used were excluded from the data. Eventually, 52 patients treated with OK432 (n=29), Ethibloc (n=5) and combination therapy (n=18) were included. The average number of sessions and duration in months of treatment was respectively 2.38 and 8.6 for OK432, 1.4 and 5.6 for Ethibloc, and 1.83 and 2.30 for dual therapy. The results were statistically significant for the difference in duration between OK432 and dual therapy. Also, 60-80% of patients reached proper results related to success, but the difference was no significant among the agents. Other demographic and anatomical variables were analyzed, not showing any difference, which supports the homogeneity of the sample. Conclusions. Despite of no significant difference in success and number of sessions among agents, longer duration of treatment with OK432 than dual therapy could mean greater health costs and probably greater disturb for patient and family (AU)


Subject(s)
Humans , Male , Female , Child , Lymphatic Abnormalities/therapy , Lymphatic Abnormalities , Radiology, Interventional/methods , Sclerosing Solutions/therapeutic use , Doxycycline/therapeutic use , Retrospective Studies , 28599 , Sclerosis/therapy , Sclerosis
12.
Bull Exp Biol Med ; 163(4): 554-560, 2017 08.
Article in English | MEDLINE | ID: mdl-28853088

ABSTRACT

The peculiarities of tissue sclerosis after injection of autologous bone marrow multipotent mesenchymal stromal cells transfected with GFP gene and stained with Vybrant CM-Dil cell membrane dye were studied by light microscopy with luminescence. The surgical intervention consisting in ligation of the great vein was followed by tissue sclerotic transformation caused by direct damage and chronic inflammation caused by the presence of slowly resorbed ligature. Injection of stromal cells after this intervention led to formation of more extensive scar. This can attest to the possibility of stromal cells differentiation into connective tissue cells, fibroblasts, and stimulation of proliferation and collagen synthesis by host fibroblasts. A decrease in the volume of dense fibrous connective tissue due to scar reorganization at latter terms cannot not excluded.


Subject(s)
Cicatrix/metabolism , Mesenchymal Stem Cells/cytology , Sclerosis/therapy , Stromal Cells/cytology , Animals , Bone Marrow Cells/cytology , Bone Marrow Cells/physiology , Cell Differentiation/physiology , Male , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/physiology , Rats
13.
Epilepsy Behav ; 69: 121-125, 2017 04.
Article in English | MEDLINE | ID: mdl-28242475

ABSTRACT

OBJECTIVE: It is not yet understood why seizures in certain patients with mesial temporal lobe epilepsy and hippocampal sclerosis (MTLE-HS) develop resistance to antiepileptic drugs (AEDs) while others achieve good seizure control with this treatment. We analyzed clinical and neuropsychological features associated with seizure control in patients with MTLE-HS who had not undergone resective surgery. METHODS: We enrolled 40 patients with medically treated MTLE-HS and retrospectively collected the following data from prospective databases: sex, febrile seizures, central nervous system infection, history of head trauma, cognitive impairment, psychiatric disturbances, history of status epilepticus, age at onset of epilepsy, aura, seizure type and frequency, electroencephalography abnormalities, HS side, AEDs, global cognitive status, and neuropsychological functions such as cognitive processing speed, attention and executive functions, verbal and visual memory, language, and visuospatial ability. These factors were compared between patients who achieved seizure control (no seizures or a >50% reduction in seizure frequency) with AED treatment and those who continued with poor seizure control (increase or no change in frequency or <50% reduction) after starting treatment. RESULTS: The factors associated with poor seizure control in the multivariate analysis were >2seizures per month before treatment (odds ratio [OR] 3.2, 95% confidence interval [CI] 1.2-4.8, p=0.04), moderate or severe cognitive impairment (OR 2.1, 95% CI 1.8-7.6, p=0.02), and impairment of >2 neuropsychological functions (OR 2.88, 95% CI 2-6.6, p=0.04). No associations were observed between poor seizure control and specific neuropsychological function impairment. CONCLUSIONS: Poor seizure control in MTLE-HS is associated with moderate-severe cognitive impairment but not with a specific profile of impairment. Recognizing poor prognostic features such as a high frequency of monthly seizures prior to starting AED treatment could help to identify patients with medically intractable MTLE-HS who may be good candidates for early epilepsy surgery.


Subject(s)
Epilepsy, Temporal Lobe/psychology , Epilepsy, Temporal Lobe/therapy , Hippocampus/pathology , Neuropsychological Tests , Seizures/psychology , Seizures/therapy , Adolescent , Adult , Anticonvulsants/therapeutic use , Cohort Studies , Epilepsy, Temporal Lobe/diagnostic imaging , Female , Hippocampus/diagnostic imaging , Humans , Male , Middle Aged , Neurosurgical Procedures/methods , Prognosis , Prospective Studies , Retrospective Studies , Sclerosis/pathology , Sclerosis/psychology , Sclerosis/therapy , Seizures/diagnostic imaging , Treatment Outcome , Young Adult
14.
Surg Obes Relat Dis ; 13(1): 21-27, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27665150

ABSTRACT

BACKGROUND: Reductions in urinary protein excretion after Roux-en-Y gastric bypass (RYGB) surgery in patients with diabetic kidney disease have been reported in multiple studies. OBJECTIVES: To determine the weight loss dependence of the effect of RYGB on urinary protein excretion by comparing renal outcomes in Zucker diabetic fatty rats undergoing either gastric bypass surgery or a sham operation with or without weight matching. SETTING: University laboratories. METHODS: Zucker diabetic fatty rats underwent surgery at 18 weeks of age. A subgroup of sham operated rats were weight matched to RYGB operated rats by restricting food intake. Urinary protein excretion was assessed at baseline and at postoperative weeks 4 and 12. Renal histology and macrophage-associated inflammation were assessed at postoperative week 12. RESULTS: Progressive urinary protein excretion was attenuated by both RYGB and diet-induced weight loss, albeit to a lesser extent by the latter. Both weight loss interventions produced equivalent reductions in glomerulomegaly, glomerulosclerosis, and evidence of renal macrophage infiltration. CONCLUSION: Weight loss per se improves renal structure and attenuates renal inflammatory responses in an experimental animal model of diabetic kidney disease. Better glycemic control post-RYGB may in part explain the greater reductions in urinary protein excretion after gastric bypass surgery.


Subject(s)
Diabetic Nephropathies/therapy , Diet, Reducing , Gastric Bypass , Weight Loss/physiology , Animals , Diabetes Mellitus, Experimental/therapy , Hypertrophy/therapy , Kidney Glomerulus/pathology , Macrophages/physiology , Male , Nephritis/therapy , Proteinuria/etiology , Random Allocation , Rats, Zucker , Sclerosis/therapy
15.
Ideggyogy Sz ; 70(11-12): 381-387, 2017 Nov 30.
Article in Hungarian | MEDLINE | ID: mdl-29870646

ABSTRACT

The aim of our case reports is to demonstrate the therapeutic use and possibilities one has with alemtuzumab, should it be used either as a first or second line therapy. Our first patient's disease in the beginning seemed to be benign. It was not the case however, over several years the diesase showed high activity both radiologically and clinically, she was treated with alemtuzumab as part of an esclationbased therapeutic strategy. The second patient's disease on the other hand showed formidable activity since the very beginning both radiologically and clinically. Therefore we were facing a very disastrous prognosis on the long run, accordingly he received alemtuzumab treatment very early into his illness.


Subject(s)
Alemtuzumab/therapeutic use , Immunologic Factors/therapeutic use , Multiple Sclerosis/therapy , Algorithms , Female , Humans , Multiple Sclerosis/diagnostic imaging , Practice Guidelines as Topic , Sclerosis/diagnostic imaging , Sclerosis/therapy
16.
Brain Stimul ; 10(1): 28-35, 2017.
Article in English | MEDLINE | ID: mdl-27693237

ABSTRACT

BACKGROUND: Transcranial direct current stimulation (tDCS) has been evaluated in medication refractory epilepsy patients. The results have been inconclusive and protocols have varied between studies. OBJECTIVE: To evaluate the safety and efficacy of two protocols of tDCS in adult patients with mesial temporal lobe epilepsy and hippocampal sclerosis (MTLE-HS). METHODS: This is a randomized placebo-controlled, double-blinded clinical trial, with 3 arms, 3 sessions, 5 sessions and placebo stimulation. Frequency of seizures (SZs), interictal epileptiform discharges (IEDs) and adverse effects (AEs) were registered before and after treatment, and at 30 and 60 days follow-up. Descriptive statistics, k-related samples, Friedman's test, and relative risk (RR) estimation were used for analysis. RESULTS: We included twenty-eight subjects (3d n = 12, 5d n = 8, placebo n = 8), 16/28 (57%) men, age 37.8(±10.9) years old. There was a significant reduction of the frequency of SZs at one (p = 0.001) and two (p = 0.0001) months following cathodal tDCS compared to baseline in the 3 arms (p = 0.0001). The mean reduction of SZ frequency at two months in both active groups was significantly higher than placebo (-48% vs. -6.25%, p < 0.008). At 3 days (-43.4% vs. -6.25%, p < 0.007) and 5 days (-54.6% vs. -6.25%, p < 0.010) individual groups showed a greater reduction of SZs. A significant IED reduction effect was found between baseline and immediately after interventions (p = 0.041) in all groups. Side effects were minor. CONCLUSIONS: Cathodal tDCS technique of 3 and 5 sessions decreased the frequency of SZs and IEDs (between baseline and immediately post-tDCS) in adult patients with MTLE-HS compared to placebo tDCS.


Subject(s)
Epilepsy, Temporal Lobe/physiopathology , Epilepsy, Temporal Lobe/therapy , Hippocampus/physiopathology , Transcranial Direct Current Stimulation/methods , Adult , Aged , Double-Blind Method , Electroencephalography/methods , Epilepsy, Temporal Lobe/pathology , Female , Follow-Up Studies , Hippocampus/pathology , Humans , Male , Middle Aged , Sclerosis/pathology , Sclerosis/physiopathology , Sclerosis/therapy
17.
Chirurg ; 87(6): 486-8, 2016 Jun.
Article in German | MEDLINE | ID: mdl-27193006

ABSTRACT

BACKGROUND: Chronic mediastinitis is a rare disorder characterized by the proliferation of fibrous tissue within the mediastinum resulting in compression of mediastinal structures. OBJECTIVE: This article gives an overview of the treatment options for chronic mediastinitis. MATERIAL AND METHODS: A literature search was carried out regarding treatment options for chronic mediastinitis RESULTS AND CONCLUSION: Little is known about the pathogenesis of chronic mediastinitis, which has hampered the development of novel therapeutic approaches. There is no convincing evidence for the success of medicinal (antifungal or conventional anti-inflammatory) therapy and it is not recommended. In cases of clinical symptoms procedures for decompression, such as endovascular or endobronchial stents or surgical procedures, such as decompression interventions or extra-anatomic bypasses should be considered. The prognosis for unilateral involvement is better than for bilateral involvement if performed in specialized centers.


Subject(s)
Mediastinitis/therapy , Anti-Inflammatory Agents/therapeutic use , Antifungal Agents/therapeutic use , Blood Vessel Prosthesis Implantation , Chronic Disease , Decompression, Surgical , Humans , Mediastinitis/diagnosis , Mediastinitis/etiology , Prognosis , Sclerosis/diagnosis , Sclerosis/etiology , Sclerosis/therapy , Stents , Superior Vena Cava Syndrome/diagnosis , Superior Vena Cava Syndrome/etiology , Superior Vena Cava Syndrome/therapy , Treatment Outcome
18.
Radiología (Madr., Ed. impr.) ; 58(supl.2): 2-14, mayo 2016. tab, ilus
Article in Spanish | IBECS | ID: ibc-153289

ABSTRACT

La ecografía se ha convertido en una herramienta sumamente útil en la valoración de masas y lesiones en la cabeza y el cuello. Permite determinar la localización anatómica, así como las características del tejido que compone las lesiones en estudio. De esta manera conseguimos orientar el diagnóstico diferencial hacia lesiones inflamatorias, neoplásicas, congénitas, traumáticas o vasculares. Sí es cierto que para establecer la extensión completa de determinadas lesiones hay que apoyarse en el escáner o la resonancia. Los procedimientos intervencionistas, gracias a la guía ecográfica principalmente, han visto crecer sus indicaciones, por lo que actualmente pueden realizarse biopsias, drenajes, infiltraciones, tratamientos mediante esclerosis y ablaciones de tumores (AU)


Ultrasonography has become extremely useful in the evaluation of masses in the head and neck. It enables us to determine the anatomic location of the masses as well as the characteristics of the tissues that compose them, thus making it possible to orient the differential diagnosis toward inflammatory, neoplastic, congenital, traumatic, or vascular lesions, although it is necessary to use computed tomography or magnetic resonance imaging to determine the complete extension of certain lesions. The growing range of interventional procedures, mostly guided by ultrasonography, now includes biopsies, drainages, infiltrations, sclerosing treatments, and tumor ablation (AU)


Subject(s)
Humans , Male , Female , Neck Injuries/surgery , Neck Injuries , Neck/surgery , Neck , Face/surgery , Face , Diagnosis, Differential , Catheter Ablation/methods , Biopsy/methods , Sclerosis/therapy , Analgesia , Image-Guided Biopsy/instrumentation , Image-Guided Biopsy/methods , Hemostasis/radiation effects , Hemostasis, Surgical
19.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 36(8): 933-937, 2016 08.
Article in Chinese | MEDLINE | ID: mdl-30640987

ABSTRACT

Objective To observe the therapeutic efficacy and safety of Chinese herbal fumigation combined with leflunomide (LEF) and prednisone (Pred) in treatment of systemic sclerosis (SSc) complicated pulmonary arterial hypertension (PAH). Methods Totally 99 SSc patients complicated early PAH were randomly assigned to the Western drugs group (WD, 49 cases) and the integrative medicine group (IM, 50 cases). Patients in the WD group took LEF (20 mg) and Pred (15 mg) , once per day. In addition to routine WD program, those in the IM group additionally received Chinese herbal fumigation. All treatment lasted for 6 months. Raynaud's phenomenon (RP) was observed in each group before and after treatment. RP score, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), pulmonary arterial systolic pressure (PASP) , and pulmonary function were compared between the two groups before and after treatment. The clinical efficacy and adverse reactions were evaluated. Results Thirteen cases were lost due to various reasons. A total of 86 patients completed this study, 41 in the WD group and 45 in the IM group. Compared with the same group before treatment, RP score, levels of ESR and CRP all decreased in the two groups after treatment (P <0. 05). Compared with the WM group after treatment, RP score, levels of ESR and CRP were obviously lowered in the IM group after treatment (P < 0. 05). Besides, lowered differences between post-pre-values of ESR, CRP, and PASP were more obviously higher, while elevated differences between post-pre-values of total lung capacity (TLC) and carbon monoxide diffusing capacity (DLCO) were more obviously higher in the IM group (P <0. 05). The total effective rate was 93. 33% (42/45) in the IM group, obviously higher than that in the WD group [70. 73% (29/41) , P <0. 05 ]. There was no statistical difference in total adverse reaction rate between the two groups (x² =0. 019, P =0. 891). Conclusion Chinese herbal fumigation combined with WD had obvious efficacy with less adverse reactions, so it was worth clinical spread.


Subject(s)
Drugs, Chinese Herbal , Hypertension, Pulmonary , Integrative Medicine , Sclerosis , Fumigation , Humans , Hypertension, Pulmonary/complications , Hypertension, Pulmonary/therapy , Sclerosis/complications , Sclerosis/therapy
20.
Contrib Nephrol ; 185: 66-75, 2015.
Article in English | MEDLINE | ID: mdl-26023016

ABSTRACT

Mesothelial cells are an integral part of the peritoneum and play an important role in maintaining its structure and functions. A number of studies have been performed to evaluate the ability of mesothelial cells to regenerate and transdifferentiate. Mesothelial cells are also involved in repairing the damage to the peritoneum as a result of surgery or peritonitis. Previous cell sheet engineering research has made it possible to transplant cells that retain their function, and stacking different types of cells in cell sheet layers has also become possible. Mesothelial cell transplantation as a means of achieving peritoneal regeneration needs to be performed under conditions in which the surface area of the visceral peritoneum is large and the area of mesothelial cell damage is small. In this chapter, we explain cell sheet engineering as a technology for transplanting cells in which a variety of intercellular adhesion and cell membrane molecules remain intact and the application of this technology to peritoneal regeneration.


Subject(s)
Epithelial Cells/transplantation , Peritoneal Dialysis/adverse effects , Peritoneum/physiology , Regeneration , Tissue Engineering/methods , Animals , Atrophy/etiology , Atrophy/therapy , Dialysis Solutions/adverse effects , Epithelial Cells/cytology , Epithelial Cells/physiology , Humans , Neovascularization, Pathologic/etiology , Neovascularization, Pathologic/therapy , Peritoneum/pathology , Peritonitis/complications , Sclerosis/etiology , Sclerosis/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...